Vivaldi Capital Management LP Crispr Therapeutics Ag Transaction History

Vivaldi Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$110.2 - $156.64 $189,764 - $269,734	-1,722 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $21,478 - $34,482	-213 Reduced 11.01%	1,722 $218,000
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $2,989 - $5,671	27 Added 1.42%	1,935 $206,000
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $152,010 - $330,522	1,908 New	1,908 $292,000
Q4 2018 Feb 13, 2019	SELL	$22.73 - $42.34 $113,786 - $211,954	-5,006 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$44.35 - $65.71 $266 - $394	6 Added 0.12%	5,006 $222,000
Q2 2018 Aug 13, 2018	BUY	$42.62 - $73.59 $213,100 - $367,950	5,000 New	5,000 $294,000

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Vivaldi Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Vivaldi Capital Management LP with notifications on news.